Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?

Investor Tips
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.

Articles You May Like

The fear of loss can cost investors big-time. Here’s how
House approves tentative labor deal to avoid rail strike, sends to Senate
Biden administration loosens Trump-era investing rules around environment, social and governance funds for 401(k) plans
Disney hiring freeze will stay in place, CEO Bob Iger tells employees
It’s been a volatile year for the market: These are the key things to know before rebalancing your portfolio